GS subjects show higher expression level of p-AMPK, PPARα and γ and PGC1α in PMBCs in comparison to age- and gender –matched control subjects. They are less likely to contract metabolic diseases or die prematurely. This evidence concerns the gene PPARGC1A and metabolic disease.